Dean Slagel - Director, Cara Therapeutics, Inc

As of July 3, 2017


What is Dean Slagel's Net Worth?

The current estimated net worth of Cara Therapeutics, Inc's Director, Dean Slagel, is estimated to be about $18.22M . Dean Slagel owns about 1,064,338 units of Cara Therapeutics, Inc common stock. In the last 3 years at Cara Therapeutics, Inc, Dean Slagel has sold an estimated value of $9.11M worth.

What is Dean Slagel's Past Insider Trading?

Dean Slagel's largest sale order was 250,000 units , worth over $6.47M on July 3, 2017. In total, Dean Slagel has made about 8 transactions over 3 years of their time at Cara Therapeutics, Inc. Dean Slagel usually trades in June, with the busiest year in 2017, 2015, 2016 and 2014.

Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

What is Dean Slagel's' Mailing Address?

  • Mailing address is C/o Esperante Ventures Po Box 30127 Limhamn V7 SE-20061 Sweden

What are Cara Therapeutics, Inc's Past Insider Trades?

Cara Therapeutics, Inc's most recent insider trade came on April 5, 2022 by Scott Terrillion who sold 1,642 units worth $19.56K . In the last 8 years, insiders at Cara Therapeutics, Inc have sold an estimated value of $26.43M and bought an estimated value of $21.23M worth of shares. Insider trading is most common in June, with the busiest year in 2020. The most active traders at the company are Phd Frederique Menzaghi, Chief Scientific OffSVP-R&D,  Derek Chalmers, President & CEO,  and Jeffrey Ives, Director .

Cara Therapeutics, Inc. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1